Cognitive impairment in early stages of multiple sclerosis

Amato, Maria Pia; Portaccio, Emilio; Goretti, Benedetta; Zipoli, Valentina; Hakiki, Bahia; Giannini, Marta; Pastò, Luisa; Razzolini, Lorenzo

doi:10.1007/s10072-010-0376-4

Cited by 168 publications

(132 citation statements)

References 18 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…However, it is often considered an "invisible" symptom of the disease that can go undetected without direct examination [12]. While those with more severe disease are at greatest risk [11,[13][14][15], all patients are vulnerable. Cognitive deficits are found even among patients with "benign" disease [16] as well as those at a very early disease stage (i.e., clinically isolated syndrome or CIS and radiologically isolated syndrome or RIS) [17,18].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Montreal Cognitive Assessment (MoCA) in Multiple Sclerosis: Relation to Clinical Features

Charvet

Taub²,

Cersosimo³

et al. 2015

J Mult Scler

View full text Add to dashboard Cite

Background: The Montreal Cognitive Assessment (MoCA) is quickly becoming the most common clinical screen for cognitive impairment. Cognitive impairment is a frequent symptom of multiple sclerosis (MS) and can be difficult to detect in routine evaluation. Although specific screening measures have been studied and established for use in MS, MS cognitive screening tools may not be implemented in a general neurology setting.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Cognitive impairment occurs in approximately 43-65% of adults with multiple sclerosis (MS) [10,11]. However, it is often considered an "invisible" symptom of the disease that can go undetected without direct examination [12].…”

Section: Introductionmentioning

confidence: 99%

The Montreal Cognitive Assessment (MoCA) in Multiple Sclerosis: Relation to Clinical Features

Charvet

Taub²,

Cersosimo³

et al. 2015

J Mult Scler

View full text Add to dashboard Cite

show abstract

“…[1][2][3] Cognitive impairments are reported already in early phases of MS and are also found in patients with clinically isolated symptoms (CIS). [4][5][6] Beside physical disabilities and comorbidities, cognitive impairments have a profound negative influence on the everyday life of the patients. For example, at work or in social relationships.…”

Section: Introductionmentioning

confidence: 99%

Immunomodulatory treatments and cognition in MS

2016

View full text Add to dashboard Cite

Cognitive impairments occur frequently and early in multiple sclerosis (MS) and contribute significantly to a reduced quality of life of patients with MS. Executive functions (EFs) play a pivotal role for the behavioral adaption to the environment and are also crucial for compensatory processes of cognitive impairments. Disease-modifying drugs (DMDs) are effective in reducing the frequency of relapses and slow the disease progression in MS. The effects of DMDs on cognitive impairments were reviewed with a special focus on EFs. Most studies show some beneficial effects of DMDs on cognition in MS, but the evidence for effects on EFs is sparse. Additionally, most studies suffer from methodological issues, small sample sizes and learning effects. We discuss that EFs may constitute a viable cognitive endpoint for cognitive impairments in MS, which could foster the early detection of subtle cognitive changes in MS. K E Y W O R D Scognition, disease-modifying drugs, executive functions, multiple sclerosis 1

show abstract

“…Sensory symptoms, visual disturbances, muscle weakness, depression, cognitive impairment, coordination, and speech disorders, severe fatigue, balance problems, and pain are among the symptoms of the disease (3). Cognitive impairment affects 40% to 65% of patients and is a major cause of disability associated with the disease (4). The most affected cognitive functions in patients with MS are attention, learning, visuospatial functions, memory, information processing speed, and executive functions (5).…”

Section: Introductionmentioning

confidence: 99%

Cognitive Impairment in Young Multiple Sclerosis and Essential Tremor Patients: A Comparative Study

Şengül¹,

Şengül²,

Yücel³

et al. 2016

tnd

View full text Add to dashboard Cite

Objective: In multiple sclerosis (MS); memory, attention, information processing speed, and executive function deficits associated with cortical demyelination and atrophy can be seen in the early phases. In essential tremor (ET) cognitive impairment associated with cerebral-thalamocortical pathway dysfunction, which is characterized by visuospatial functions, verbal memory, and executive functions were seen. We aimed to evaluate cognitive impairment in patients with MS and ET, and to compare the features of impairment. Materials and Methods:Thirty patients ET (mean age 27.7±6.8 years), 30 patients with MS (mean age 32.4±6.6 years) and 20 healthy controls (mean age 28.81±7.3 years) were recruited for the study. For assessing cognitive impairment, the Montreal Cognitive Assessment (MoCA) test was applied to all participants. For grading the disease, the Fahn-Tolosa-Marin Tremor Rating Scale was used in the ET group, and the Expanded Disability Status Scale was used in the MS group. Results:The total MoCA mean scores in patients with MS was 22.4±4.34, 25.8±2.7 in patients with ET, and 28.2±1.8 in controls. When we compared the patients with the controls, the patients' mean score was lower than in the controls. Cognitive impairment in patients with MS was more apparent than in patients with ET. Naming, attention, language, and delayed recall subgroups in patients with MS were more affected than in patients with ET. Conclusion:In this present study, we determined cognitive impairment can be seen in both group of patients, and MS can cause more prominent deficit than ET. In addition, our study confirms that cognitive impairment in MS and ET can be detected using the MoCA test. Keywords: Multiple sclerosis, essential tremor, cognitive impairment, Montreal Cognitive Assessment testAmaç: Multipl sklerozda (MS) kortikal demiyelinizasyon ve atrofi ile ilişkili bellek, dikkat, bilgi işleme hızı ve yönetici işlev bozuklukları hastalığın ilk dönemlerinden itibaren görülmektedir. Esansiyel tremorda (ET) ise serebello-talamo-kortikal yol disfonksiyonunu ile viziospasyal fonksiyonlar, verbal hafıza ve yine yürütücü işlevlerin bozulması ile karakterize kognitif etkilenmenin olduğu gösterilmiştir. Çalışmamızda MS ve ET hastalarında kognitif bozukluğunun değerlendirilmesini ve özellikleri açısından karşılaştırılmasını amaçladık. Gereç ve

show abstract

Cognitive impairment in early stages of multiple sclerosis

Cited by 168 publications

References 18 publications

The Montreal Cognitive Assessment (MoCA) in Multiple Sclerosis: Relation to Clinical Features

The Montreal Cognitive Assessment (MoCA) in Multiple Sclerosis: Relation to Clinical Features

Immunomodulatory treatments and cognition in MS

Cognitive Impairment in Young Multiple Sclerosis and Essential Tremor Patients: A Comparative Study

Contact Info

Product

Resources

About